The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1283
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Simcor: A Niacin/Simvastatin Combination

The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin (Niaspan) with a generic statin. Niaspan/simvastatin (Simcor – Abbott) is approved for use in patients with hypercholesterolemia or mixed dyslipidemia (high LDL-cholesterol, low HDL-cholesterol and high serum triglycerides). Niaspan/lovastatin (Advicor) was marketed previously for the same indications.1

STATINS — Statins are more effective than other drugs in lowering LDL-C, and they also lower triglycerides. Most statins increase HDL-C only modestly. Statins have dose-related differences in how much they lower LDL-C. A lovastatin dose of 20 mg usually lowers LDL-C by 25%-30%; a maximum dose of 80 mg lowers it by 35%-40%. A simvastatin dose of 20 mg lowers LDL-C by 35%-40%; a maximum dose of 80 mg lowers it by 45%-50%.2

NIACIN — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1283
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian